These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25836940)

  • 21. [Systemic chemotherapy of urothelial cancer].
    Wolff JM; Jakse G
    Urologe A; 1992 May; 31(3):W19-24. PubMed ID: 1615589
    [No Abstract]   [Full Text] [Related]  

  • 22. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
    Pectasides D; Pectasides M; Economopoulos T
    Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic chemotherapy in regionally advanced bladder cancer. Theoretical considerations and results.
    Scher HI
    Urol Clin North Am; 1992 Nov; 19(4):747-59. PubMed ID: 1441029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic bladder cancer: anything new?
    Calabrò F; Sternberg CN
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):304-9. PubMed ID: 22643704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of advanced bladder cancer in the era of targeted therapies.
    Soave A; Engel O; Von Amsberg G; Becker A; Dahlem R; Shariat SF; Fisch M; Rink M
    Minerva Urol Nefrol; 2015 Jun; 67(2):103-15. PubMed ID: 25604695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current developments in the medical treatment of advanced urothelial carcinoma of the bladder].
    Schmid SC; Gschwend JE; Retz M;
    Aktuelle Urol; 2014 Jan; 45(1):55-63; quiz 64-5. PubMed ID: 24500963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment strategies for metastatic patients in bladder cancer].
    Théodore C
    Bull Cancer; 2010; 97 Suppl Cancer de la vessie():27-33. PubMed ID: 20534387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
    Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
    Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
    Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
    Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel agents for muscle-invasive and advanced urothelial cancer.
    Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
    BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving role of chemotherapy in advanced urothelial cancer.
    Calabrò F; Sternberg CN
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New therapeutic challenges in advanced bladder cancer.
    Bellmunt J; Petrylak DP
    Semin Oncol; 2012 Oct; 39(5):598-607. PubMed ID: 23040256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in advanced urothelial cancer.
    Chee KG; Cambio A; Lara PN
    Curr Opin Urol; 2005 Sep; 15(5):342-9. PubMed ID: 16093860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic chemotherapy for advanced bladder cancer: update and controversies.
    Garcia JA; Dreicer R
    J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bladder cancer and new drugs].
    Massard C; Albouy B; Gross-Goupil M; Ravaud A
    Bull Cancer; 2010; 97 Suppl Cancer de la vessie():43-50. PubMed ID: 20534389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
    Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
    Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy for advanced bladder cancer.
    Roth BJ
    Semin Oncol; 1996 Oct; 23(5):633-44. PubMed ID: 8893874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress and controversies in chemotherapy of advanced unresectable and/or metastatic carcinoma of the bladder.
    Akaza H
    Prog Clin Biol Res; 1988; 269():539-49. PubMed ID: 3293070
    [No Abstract]   [Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy in muscle-invasive bladder cancer: ready for prime time?
    Pouessel D; Mongiat-Artus P; Culine S
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):288-94. PubMed ID: 23022113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.